Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects

13 Aug 2019

Abstract excerpt

In 2011, the Vysis Break Apart ALK fluorescence in situ hybridization (FISH) assay was approved by the United States Food and Drug Administration as a companion diagnostic for detecting ALK rearrangement in lung cancer patients who may benefit from treatment of tyrosine kinase inhibitor therapy. This assay is the current “gold standard”. According to updated ALK testing guidelines from the College of American...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31412611
DOI: 10.3390/ijms20163939

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical AspectsPMID 31412611Read ↗

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testingSemantic proximity Read ↗

IHC versus FISH versus NGS to detect ALK gene rearrangement in NSCLC: all questions answered?Semantic proximity Read ↗

ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancerSemantic proximity Read ↗

ALK in lung cancer: past, present, and future.Semantic proximity Read ↗

ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision makingSemantic proximity Read ↗

Role of Fluorescence in situ Hybridization in Lung Cancer CytologySemantic proximity Read ↗

National Working Group Meeting on ALK diagnostics in lung cancer.Semantic proximity Read ↗

Concordance of Immunohistochemistry and Fluorescence In Situ Hybridization in the Detection of Anaplastic Lymphoma Kinase (ALK) and Ros Proto-oncogene 1 (ROS1) Gene Rearrangements in Non-Small Cell Lung Carcinoma: A 4.5-Year Experience Highlighting Challenges and Pitfalls.Semantic proximity Read ↗

Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive ImmunohistochemistrySemantic proximity Read ↗

Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancersSemantic proximity Read ↗

ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice.Semantic proximity Read ↗

Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.